The active ingredient is teriflunomide. Aubagio works by selectively interfering with the ability of white blood cells (lymphocytes) to produce the disease response and nerve damage that ultimately leads to relapses.
In clinical trials, Aubagio demonstrated a significant positive effect compared with placebo on the 3 measures of MS disease activity:
Further information about the trials and results can be found at www.aubagio.com/teriflunomide-rms/
Aubagio is available in tablet form in two strengths; 7mg and 14mg. Your prescribing specialist will recommend the appropriate dosage. Tablets are taken once daily with or without food. It should be taken at the same time each day and with a glass of water.
You should tell your doctor:
Tell your doctor or pharmacist if you notice any of the following and they worry you:
Special Authority must be approved by the Multiple Sclerosis Treatment Assessment Committee (MSTAC) before funding is approved. Applications will be considered by MSTAC at its regular meetings and approved subject to eligibility according to the Entry and Stopping criteria.
For details of the current criteria and how to apply for funded treatment see Disease Modifying Treatment Special Authority Criteria
It is often helpful to review how other people with MS have liked or tolerated a treatments and the benefits and side effects they have experienced.
Patients Like Me – Terifluromide
Reports from health professionals are preferred as doctors and other prescribers, pharmacists and nurses usually are able to provide more detailed information about the medications in use and other medical history from patient records that are helpful in evaluating the adverse reaction. However anyone may report a suspected adverse event or reaction to medication taken to the Centre for Adverse Reactions Monitoring (CARM).
For instructions and further information https://nzphvc.otago.ac.nz/reporting/